STOCK TITAN

Immutep Limited American Depositary Shares - IMMP STOCK NEWS

Welcome to our dedicated page for Immutep American Depositary Shares news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep American Depositary Shares stock.

Immutep Limited (NASDAQ: IMMP) is a globally active biotechnology company focusing on the development of innovative immunotherapy products for cancer and autoimmune diseases. Listed on both the Australian Stock Exchange and the Nasdaq Global Market in the U.S., Immutep is at the forefront of personalized bio-therapeutic treatment options.

At the core of Immutep's research and development is the LAG-3 immune control mechanism, crucial for the regulation of the T cell immune response. The company's flagship product, IMP321, a T cell immunostimulatory factor (APC activator), has completed Phase II clinical trials for cancer chemo-immunotherapy. This product is designed to enhance the body's immune response to cancer, providing a novel treatment option for patients.

In addition to IMP321, Immutep is advancing several other LAG-3 related products. These include IMP701, a blocking anti-LAG-3 antibody for cancer currently in Phase I clinical trials, and CVac, a personalized immunocellular therapeutic being investigated for the treatment of epithelial cancer. The development of these products is supported through partnerships with large pharmaceutical companies, aiming to accelerate the availability of these innovative treatments.

Immutep's operations are headquartered in Australia, with the majority of its revenue derived from product sales. The company remains committed to maximizing shareholder value through its technological expertise and robust pipeline of products.

For investors, Immutep represents a significant opportunity in the biotechnology sector, with its cutting-edge research and promising clinical advancements poised to make a substantial impact on cancer and autoimmune disease treatment.

Rhea-AI Summary

Immutep Limited (NASDAQ: IMMP) announced promising interim results from the Phase II TACTI-002 trial for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC). Key findings include a median overall survival of 9.7 months and a 36.5% survival rate at 18 months for patients receiving efti combined with pembrolizumab. The study, which involves 36 patients, shows favorable safety and tolerability compared to traditional chemotherapy. These results support the potential of efti as a viable treatment option for advanced NSCLC patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Rhea-AI Summary

Immutep Limited (NASDAQ: IMMP) announced significant progress in its clinical trials for cancer therapies. The Phase II TACTI-002 trial demonstrated a 38.6% Overall Response Rate for efti in 1st line non-small cell lung cancer patients. Additionally, biomarker analysis from the Phase IIb AIPAC trial confirmed that efti activates the immune system, correlating with improved survival rates. The company remains well-funded, with approximately $80 million in cash, ensuring operational stability into early 2024. Four notable oncologists have joined the Clinical Advisory Board to enhance strategic direction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
none
-
Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has announced the grant of a new patent by the Japanese Patent Office for its pre-clinical candidate IMP761, targeting autoimmune diseases. The patent is valid until September 1, 2036, and follows a similar grant in Europe. CEO Marc Voigt highlighted the importance of protecting IMP761, which operates as a LAG-3 agonist, aiming to treat the underlying causes of autoimmune diseases. The company is collaborating with Northway Biotech for GMP compliant manufacturing ahead of clinical testing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.31%
Tags
none
Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced new data from the Phase II TACTI-002 trial focusing on non-small cell lung cancer (NSCLC) patients. This data will be presented at the IASLC 2022 World Conference on Lung Cancer in Vienna from August 6-9, 2022. The poster's abstract will be available on July 8, 2022. The TACTI-002 trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients with second line PD-1/PD-L1 refractory metastatic NSCLC. Immutep is dedicated to developing innovative immunotherapy treatments for cancer and autoimmune diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary

Immutep has announced positive results from the Phase II TACTI-002 trial, evaluating the combination of eftilagimod alpha (efti) and pembrolizumab (KEYTRUDA) in 1st line non-small cell lung cancer (NSCLC) patients. The study met its primary objective with an Overall Response Rate (ORR) of 38.6% across 114 patients, exceeding historical anti-PD-1 monotherapy results. Notably, responses were observed in patients with low or negative PD-L1 expression. The treatment was reported safe and well-tolerated, supporting further late-stage development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.32%
Tags
-
Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) will host a global webcast on June 7, 2022, to discuss new data from its Phase II TACTI-002 trial for non-small cell lung cancer (NSCLC). This data will be presented at the ASCO 2022 Annual Meeting on June 3, 2022. Immutep's CEO Marc Voigt and other executives will speak during the webcast. Their lead product, eftilagimod alpha, is a LAG-3 related immunotherapy treatment for cancer and autoimmune diseases. The company aims to enhance treatment options for patients and value for shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
Rhea-AI Summary

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has released interim data from its Phase II TACTI-002 trial, demonstrating positive antitumor activity of eftilagimod alpha in first-line non-small cell lung cancer (NSCLC) patients. The Overall Response Rate (ORR) improved to 37.3% among the 75 patients, up from 36.1% reported at ASCO 2021, with a Disease Control Rate (DCR) of 73.3%. Efti combined with pembrolizumab remains safe and well-tolerated. Data from all 114 patients will be presented on June 3, 2022, along with updates on the ongoing Phase IIb TACTI-003 trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.64%
Tags
none
-
Rhea-AI Summary

Immutep Limited (NASDAQ: IMMP) announced its participation in several upcoming investor conferences, showcasing its advancements in immunotherapy for cancer and autoimmune diseases. Key events include:

  • Wilsons Rapid Insights: 26 May 2022, in-person, with Marc Voigt and Deanne Miller presenting.
  • Jefferies Australia MedTech/Biotech Summit: 26-27 May 2022, virtual presentation by Marc Voigt.
  • Jefferies Global Healthcare Conference: 8-10 June 2022, in-person, with a live webcast on 10 June.

Immutep is at the forefront of developing LAG-3 related immunotherapy solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.57%
Tags
conferences
-
Rhea-AI Summary

Immutep announced the appointment of four new members to its Clinical Advisory Board (CAB), enhancing its strategic resources for advancing LAG-3-related immunotherapy treatments. The new members, experts in oncology and immunotherapy, will focus on late-stage development programs for the lead product, eftilagimod alpha. This move aims to strengthen Immutep's position as a leader in innovative cancer therapies, especially targeting metastatic breast and non-small cell lung carcinomas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
management
Rhea-AI Summary

Immutep reported results from its Phase IIb AIPAC trial, demonstrating a statistically significant increase in immune response biomarkers such as monocyte and CD8 T cell counts in the efti treatment group compared to placebo. These biomarkers are correlated with improved overall survival (OS), as shown in an exploratory analysis identifying six patient subgroups that benefit from the treatment. Notably, five subgroups showed significant OS improvements, with ALC emerging as a potential predictor for survival.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.92%
Tags
none

FAQ

What is the current stock price of Immutep American Depositary Shares (IMMP)?

The current stock price of Immutep American Depositary Shares (IMMP) is $2.03 as of December 20, 2024.

What is the market cap of Immutep American Depositary Shares (IMMP)?

The market cap of Immutep American Depositary Shares (IMMP) is approximately 311.3M.

What is Immutep Limited?

Immutep Limited is a biotechnology company developing innovative immunotherapy products for cancer and autoimmune diseases.

What products does Immutep specialize in?

Immutep specializes in products based on the LAG-3 immune control mechanism, including IMP321 for cancer chemo-immunotherapy, and other LAG-3 related products like IMP701 and CVac.

What is the LAG-3 immune control mechanism?

The LAG-3 immune control mechanism is crucial for regulating the T cell immune response and is used by Immutep in developing therapies for cancer and autoimmune diseases.

What is IMP321?

IMP321 is a T cell immunostimulatory factor (APC activator) developed by Immutep for cancer chemo-immunotherapy. It has completed Phase II clinical trials.

What are the other key products in Immutep's pipeline?

Other key products include IMP701, a blocking anti-LAG-3 antibody for cancer, and CVac, a personalized immunocellular therapeutic for epithelial cancer.

With which markets is Immutep affiliated?

Immutep is listed on the Australian Stock Exchange and the Nasdaq Global Market in the U.S.

Where is Immutep headquartered?

Immutep is headquartered in Australia.

What are Immutep's key partnerships?

Immutep collaborates with large pharmaceutical companies to develop and bring its products to market.

How does Immutep generate revenue?

Immutep generates the majority of its revenue from the sale of its biotechnology products.

Why should investors consider Immutep?

Investors should consider Immutep for its cutting-edge research, promising clinical advancements in immunotherapy, and strategic partnerships.

Immutep Limited American Depositary Shares

Nasdaq:IMMP

IMMP Rankings

IMMP Stock Data

311.28M
145.44M
0.01%
6.26%
3.53%
Biotechnology
Healthcare
Link
United States of America
Sydney